Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 7, 2026, 9:14 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–7 of 7 matching trials from the live ClinicalTrials.gov search.
Conditions
Epithelial Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Cancer
Interventions
DPX-Survivac, DPX-Survivac(Aqueous), Cyclophosphamide
Biological · Drug
Lead sponsor
ImmunoVaccine Technologies, Inc. (IMV Inc.)
Industry
Eligibility
18 Years and older · Female only
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
2
States / cities
Mineola, New York • New York, New York
Conditions
Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Cancer
Interventions
DPX-Survivac, low dose cyclophosphamide (oral)
Biological · Drug
Lead sponsor
ImmunoVaccine Technologies, Inc. (IMV Inc.)
Industry
Eligibility
18 Years and older · Female only
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
5
States / cities
Buffalo, New York • Mineola, New York • Durham, North Carolina + 2 more
Conditions
Ovarian Neoplasms, Breast Neoplasms, Prostatic Neoplasms
Interventions
DPX-0907 consists of 7 tumor-specific HLA-A2-restricted peptides, a universal T Helper peptide, a polynucleotide adjuvant, a liposome and Montanide ISA51 VG
Biological
Lead sponsor
ImmunoVaccine Technologies, Inc. (IMV Inc.)
Industry
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
5
States / cities
Chicago, Illinois • Buffalo, New York • Durham, North Carolina + 2 more
Conditions
Ovarian Cancer, Hepatocellular Carcinoma, Non-small Cell Lung Cancer, Bladder Cancer, Microsatellite Instability-High
Interventions
DPX-Survivac, Cyclophosphamide, Pembrolizumab
Other · Drug
Lead sponsor
ImmunoVaccine Technologies, Inc. (IMV Inc.)
Industry
Eligibility
18 Years and older
Enrollment
184 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
15
States / cities
Tucson, Arizona • Los Angeles, California • Boca Raton, Florida + 12 more
Conditions
Platinum-resistant Epithelial Ovarian Cancer
Interventions
Maveropepimut-S, Cyclophosphamide 50mg
Other · Drug
Lead sponsor
ImmunoVaccine Technologies, Inc. (IMV Inc.)
Industry
Eligibility
18 Years and older · Female only
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
4
States / cities
Palo Alto, California • Ocala, Florida • Mineola, New York + 1 more
Conditions
Recurrent Epithelial Ovarian Cancer, Recurrent Fallopian Tube Cancer, Recurrent Peritoneal Cancer
Interventions
DPX-Survivac, Cyclophosphamide, Epacadostat (INCB024360)
Other · Drug
Lead sponsor
ImmunoVaccine Technologies, Inc. (IMV Inc.)
Industry
Eligibility
18 Years and older · Female only
Enrollment
85 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2025
U.S. locations
6
States / cities
Palo Alto, California • Augusta, Georgia • New York, New York + 3 more
Conditions
Relapsed Diffuse Large B-cell Lymphoma, Refractory Diffuse Large B-cell Lymphoma
Interventions
DPX-Survivac, Pembrolizumab, CPA
Drug
Lead sponsor
ImmunoVaccine Technologies, Inc. (IMV Inc.)
Industry
Eligibility
18 Years and older
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
17
States / cities
Fountain Valley, California • Boca Raton, Florida • Hollywood, Florida + 13 more